Clinical Guidelines

The Oral GLP‑1 Era Has Arrived 

And chromatographers are about to be very busy…

Share

The FDA's recent approval of oral GLP-1 formulations marks a pivotal change in drug formulation and analytical expectations, shifting from solely injectable biologics. The new oral peptides demand more advanced stability, impurity testing, and control over degradation paths. Analytical complexity increases, necessitating enhanced methodologies such as multi-dimensional chromatography and high-resolution mass spectrometry. Companies must adapt to meet rising regulatory scrutiny while ensuring drug efficacy, as ignorance of impurity profiles poses significant business risks.

Original Source(s)

The Oral GLP‑1 Era Has Arrived 

  • by Sean Orlowicz

  • March 12, 2026

Related Content

Sleep Duration Signals Metabolic Change

Weekend sleep recovery shows mixed metabolic associations depending on weekday sleep duration.

Empagliflozin Tested in Real-World Data

Investigators assess whether EMPA-REG findings extend to broader patients with type 2 diabetes.

SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis

A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation